TY - JOUR
T1 - Optimization of Biomimetic, Leukocyte-Mimicking Nanovesicles for Drug Delivery Against Colorectal Cancer Using a Design of Experiment Approach
AU - Rampado, Riccardo
AU - Biccari, Andrea
AU - D’Angelo, Edoardo
AU - Collino, Federica
AU - Cricrì, Giulia
AU - Caliceti, Paolo
AU - Giordano, Federica
AU - Taraballi, Francesca
AU - Pucciarelli, Salvatore
AU - Agostini, Marco
N1 - Funding Information:
This work was supported by Fondazione CARIPARO (Pediatric Research Grant, 2016–2018) and by Università degli Studi di Padova, Budget Integrato per la Ricerca dei Dipartimenti: Grant BIRD199592.
Funding Information:
The authors would like to thank the Research Pediatric Institute “Città Della Speranza” and the Department of Pharmaceutical Sciences at University of Padova for supporting the present study.
Publisher Copyright:
Copyright © 2022 Rampado, Biccari, D’Angelo, Collino, Cricrì, Caliceti, Giordano, Taraballi, Pucciarelli and Agostini.
PY - 2022/6/8
Y1 - 2022/6/8
N2 - The development of biomimetic nanoparticles (NPs) has revolutionized the concept of nanomedicine by offering a completely new set of biocompatible materials to formulate innovative drug delivery systems capable of imitating the behavior of cells. Specifically, the use of leukocyte-derived membrane proteins to functionalize nanovesicles (leukosomes) can enable their long circulation and target the inflamed endothelium present in many inflammatory pathologies and tumors, making them a promising and versatile drug delivery system. However, these studies did not elucidate the critical experimental parameters involved in leukosomes formulation. In the present study, we approached the preparation of leukosomes using a design of experiment (DoE) method to better understand the influence of experimental parameters on leukosomes features such as size, size distribution, and protein loading. We also validated this formulation technologically and tested its behavior in in vitro colorectal cancer (CRC) models, including CRC patient-derived tumor organoids (PDOs). We demonstrated leukosomes biocompatibility, endothelium adhesion capability, and tumor target in three-dimensional (3D) settings using CRC cell lines. Overall, our study offers a novel conceptual framework for biomimetic NPs using a DoE strategy and consolidates the high therapeutic potential of leukosomes as a viable drug delivery system for anti-inflammatory and antineoplastic applications.
AB - The development of biomimetic nanoparticles (NPs) has revolutionized the concept of nanomedicine by offering a completely new set of biocompatible materials to formulate innovative drug delivery systems capable of imitating the behavior of cells. Specifically, the use of leukocyte-derived membrane proteins to functionalize nanovesicles (leukosomes) can enable their long circulation and target the inflamed endothelium present in many inflammatory pathologies and tumors, making them a promising and versatile drug delivery system. However, these studies did not elucidate the critical experimental parameters involved in leukosomes formulation. In the present study, we approached the preparation of leukosomes using a design of experiment (DoE) method to better understand the influence of experimental parameters on leukosomes features such as size, size distribution, and protein loading. We also validated this formulation technologically and tested its behavior in in vitro colorectal cancer (CRC) models, including CRC patient-derived tumor organoids (PDOs). We demonstrated leukosomes biocompatibility, endothelium adhesion capability, and tumor target in three-dimensional (3D) settings using CRC cell lines. Overall, our study offers a novel conceptual framework for biomimetic NPs using a DoE strategy and consolidates the high therapeutic potential of leukosomes as a viable drug delivery system for anti-inflammatory and antineoplastic applications.
KW - biomimetic
KW - colorectal cancer
KW - design of experiment
KW - drug delivery
KW - inflammation
KW - nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=85133382397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133382397&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2022.883034
DO - 10.3389/fbioe.2022.883034
M3 - Article
C2 - 35757799
AN - SCOPUS:85133382397
SN - 2296-4185
VL - 10
SP - 883034
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 883034
ER -